Stockreport

Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
PDF PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAAT2002, an open-label Pha [Read more]